The textbook of pharmaceutical medicine

書誌事項

The textbook of pharmaceutical medicine

edited by John Parry Griffin

Wiley-Blackwell, 2009

6th ed

大学図書館所蔵 件 / 3

この図書・雑誌をさがす

注記

"BMJ Books."--t.p.

Includes bibliographical references and index

HTTP:URL=http://www.loc.gov/catdir/enhancements/fy0917/2009024878-b.html Information=Contributor biographical information

HTTP:URL=http://www.loc.gov/catdir/enhancements/fy0917/2009024878-d.html Information=Publisher description

内容説明・目次

内容説明

The Textbook of Pharmaceutical Medicine is a standard reference for all those working in pharmaceutical medicine and the recognised text for the UK Faculty of Pharmaceutical Medicine Diploma. This is a comprehensive volume covering the processes by which medicines are developed, tested and approved. Regulations for drug development in the UK, EU, USA, Australia and Japan are discussed, providing relevant information for drug approval in the main continents where new drugs are developed. The chapters are written by leading academics, medical directors and lawyers, providing authoritative and in-depth information for trainees on the Faculty course, and for physicians working in the pharmaceutical industry. As well as thorough updating of the regulatory chapters, the 6th edition includes chapters on these vital new areas: Paediatric regulation Ethics Due diligence and the pharmaceutical physician

目次

Part I: Research and development. Introduction: the development of pharmaceutical medicine as a specialty ( Susan Bews and Huw Jones ). 1 Discovery of new medicines ( Anand S Dutta ). 2 Pharmaceutical development ( Gavin Halbert ). 3 Preclinical safety testing ( Lutz Mueller and David J Tweats ). 4 Exploratory development ( John Posner ). 5 Clinical pharmacokinetics ( Paul Rolan and Valeria Rolan ). 6 Purpose and design of clinical trials ( Roger A Yates and Steve Warrington ). 7 Conduct of clinical trials: good clinical practice ( Roger A Yates and Steve Warrington ). 8 Medical statistics ( Andrew P Grieve ). 9 Development of medicines: full development ( Alan G Davies and Peter D Stonier ). Part II: Medical department issues. 10 The medical department ( Peter D Stonier ). 11 Medical marketing ( David Galloway ). 12 Information and promotion ( Charles de W et). 13 The supply of unlicensed medicines for particular patient use ( Ian Dodds-Smith, Amanda Wearing and John O'Grady ). 14 Ethics of human experimentation ( Duncan Vere ). 15 Legal and ethical issues relating to medicinal products ( David Marks, Nick Beckett, Sarah Hanson and Shuna Mason ). 16 The safety of medical products ( A. Peter Fletcher and Susan Shaw ). Part III: Regulatory aspects. 17 History of drug regulation in the United Kingdom ( John P Griffin and Rashmi R Shah ). 18 Regulation of human medicinal products in the European Union ( John P Griffin and Rashmi R Shah ). 19 Paediatric regulation ( Heike Rabe ). 20 European regulation of medical devices ( Christopher JS Hodges ). 21 Technical requirements for registration of pharmaceuticals for human use: the ICH process ( Dean W G Harron ). 22 The regulation of drug products by the United States Food and Drug Administration ( Peter Barton Hutt ). 23 The US FDA in the drug development, evaluation and approval process ( Richard N Spivey, Judith K Jones, William Wardell and William Vodra ). 24 Past evolution and future prospects of the Pharma Industry and its regulation in the USA ( William Wardell, William Vodra, Judith K Jones and Richard N Spivey ). 25 Regulatory and clinical trial systems in Japan ( Yuichi Kubo ). 26 The regulation of therapeutic products in Australia ( Janice Hirshorn and Deborah Monk ). 27 Pharmaceutical medicine in emerging markets ( N. Shreeharan ). Part IV: Pharmacoeconomic and other issues. 28 Economics of healthcare ( Carole Bradley-Kennedy and Jane R Griffin ). 29 Controls on NHS medicines prescribing and expenditure in the UK (a historical perspective) with some international comparisons ( John P Griffin and Jane R Griffin ). 30 Due diligence and the pharmaceutical physician ( Geoff Barker ). Appendix 1 Declaration of Helsinki. Appendix 2 Code of Practice for the Pharmaceutical Industry. Appendix 3 Guidelines and Documentation for Implementation of Clinical Trials. Appendix 4 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001.

「Nielsen BookData」 より

詳細情報

ページトップへ